Researchers at the University of Texas Health Science Center at San Antonio (UT Health San Antonio) have identified a potential pathophysiological link between the gut microbiome and the pathogenesis of lupus (Systemic Lupus Erythematosus — SLE), opening new horizons for the treatment of this autoimmune disease. According to a study published in the journal Nature Communications, patients with lupus exhibit a significant reduction in the population of Faecalibacterium prausnitzii, one of the primary commensal bacteria of the gut ecosystem. In animal models, the reintroduction of this microorganism substantially decreased the levels of disease activity biomarkers, positioning F. prausnitzii as a promising probiotic candidate for lupus therapy.
Systemic lupus erythematosus is a chronic, multisystem autoimmune disease affecting approximately 1.5 million individuals in the United States alone. During the course of the disease, the immune system aberrantly attacks the body’s healthy tissues and organs. This pathological process can involve the joints, skin, kidneys, heart, lungs, spleen, and the central nervous system. The clinical course of lupus is characterized by high heterogeneity, which frequently impedes timely diagnosis, while current management is predominantly oriented toward symptom control and the prevention of irreversible organ damage. Standard ongoing therapies rely on immunosuppressants and corticosteroids; however, their prolonged administration is associated with severe metabolic, cardiovascular, and infectious complications. Consequently, the discovery of safe, targeted therapeutic alternatives remains a paramount priority in contemporary rheumatology and clinical immunology.
Evidence accumulated over the past decade indicates that the pathogenesis of systemic lupus erythematosus (SLE) is significantly linked to gut microbiota imbalance (dysbiosis). In this context, various studies have already characterized at least three bacterial strains whose population shifts are closely associated with disease progression. The research team at UT Health San Antonio established that the abundance of Faecalibacterium prausnitzii is markedly diminished in the gut microbiome of patients with SLE. This commensal bacterium is distinguished by its anti-inflammatory properties and participates in the fermentation of dietary fibers, a process that yields butyrate — a short-chain fatty acid (SCFA) that serves as the primary energy source for colonic epithelial cells. Butyrate is critically important for maintaining the structural and functional integrity of the protective mucin barrier, thereby supporting intestinal mucosal homeostasis and limiting the development of pathological immune responses. Consequent to the depletion of F. prausnitzii, fiber metabolism is impaired, butyrate production decreases, the mucin barrier is compromised, intestinal permeability increases, and a pro-inflammatory microenvironment is established, which drives the progression of autoimmune processes. Although the obligate anaerobiosis (extreme sensitivity to oxygen) of F. prausnitzii complicates its integration into standard probiotic formulations, the future elucidation of its bioactive metabolites paves the way for the development of microbiome-targeted, less toxic therapeutic strategies.
This therapeutic potential is further substantiated by preclinical experimental outcomes, wherein the reintroduction of Faecalibacterium prausnitzii in animal models partially restored immune regulation, significantly reduced disease activity biomarkers, and demonstrated organoprotective effects on the kidneys and spleen. The gathered data suggest that the therapeutic efficacy of the bacterium is likely mediated by both the restoration of the intestinal epithelial barrier function and the modulation of systemic immune homeostasis.
Despite the promising results obtained at the preclinical stage, translating this approach into clinical practice faces substantial barriers. Faecalibacterium prausnitzii is characterized by extreme oxygen lability, rapidly losing biological activity, and is currently absent from widely available commercial probiotic preparations. Consequently, its therapeutic validation necessitates the development of stable pharmaceutical formulations, the determination of optimal dosing regimens, and the systematic evaluation of long-term clinical efficacy. In the next phase of research, the authors plan to identify the specific bioactive metabolites responsible for immune regulation and the modulation of inflammatory responses, as well as to analyze the multilevel interactions between dietary carbohydrates, the gut microbiome, and the immune system. Thus, this discovery may serve as a foundation for the development of microbiome-based, more targeted therapeutic strategies for the management of systemic lupus erythematosus with a more favorable safety profile.
Source: medicalxpress.com
